Arcus Biosciences, Inc.
- Market cap
- $3.52B
- 52w range
- $13.61 - $31.74
- Beta
- 0.80
- Sector
- Healthcare
- Data quality
- 83/100
- fair value estimate
- $11.21
- Margin of safety
- -54.1%
- Moat score
- 15/100
- Return on equity
- -70.0%
- Profit margin
- -156.4%
- Debt / equity
- 0.44
- Revenue growth
- -39.3%
- Analyst target
- $35.75
- Target upside
- +46.3%
- Analysts
- 12
About Arcus Biosciences, Inc.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Valuation
Derived from filed metrics · High confidence (83% of the inputs available)
Moat, fair value and rating computed by our valuation engine (ported from the original Python model).